aveni-ai/aveni-bench-convfinqa huggingface dataset:
notes to consolidated financial statements 2014 ( continued ) ( amounts in millions , except per share amounts ) a summary of the remaining liability for the 2007 , 2003 and 2001 restructuring programs is as follows : program program program total .

1	2007 program	2003 program	2001 program	total
2	liability at december 31 2006	$ 2014	$ 12.6	$ 19.2	$ 31.8
3	net charges ( reversals ) and adjustments	19.1	-0.5 ( 0.5 )	-5.2 ( 5.2 )	13.4
4	payments and other1	-7.2 ( 7.2 )	-3.1 ( 3.1 )	-5.3 ( 5.3 )	-15.6 ( 15.6 )
5	liability at december 31 2007	$ 11.9	$ 9.0	$ 8.7	$ 29.6
6	net charges and adjustments	4.3	0.8	0.7	5.8
7	payments and other1	-15.0 ( 15.0 )	-4.1 ( 4.1 )	-3.5 ( 3.5 )	-22.6 ( 22.6 )
8	liability at december 31 2008	$ 1.2	$ 5.7	$ 5.9	$ 12.8

1 includes amounts representing adjustments to the liability for changes in foreign currency exchange rates . other reorganization-related charges other reorganization-related charges relate to our realignment of our media businesses into a newly created management entity called mediabrands and the 2006 merger of draft worldwide and foote , cone and belding worldwide to create draftfcb . charges related to severance and terminations costs and lease termination and other exit costs . we expect charges associated with mediabrands to be completed during the first half of 2009 . charges related to the creation of draftfcb in 2006 are complete . the charges were separated from the rest of our operating expenses within the consolidated statements of operations because they did not result from charges that occurred in the normal course of business. .

Previous questions in this conversation: what was the value of liability in 2007? what was it in 2003?
Previous answers: 1.2 5.7
Question: what is the sum of those 2 years?
Answer: 6.9
notes to consolidated financial statements 2014 ( continued ) ( amounts in millions , except per share amounts ) a summary of the remaining liability for the 2007 , 2003 and 2001 restructuring programs is as follows : program program program total .

1	2007 program	2003 program	2001 program	total
2	liability at december 31 2006	$ 2014	$ 12.6	$ 19.2	$ 31.8
3	net charges ( reversals ) and adjustments	19.1	-0.5 ( 0.5 )	-5.2 ( 5.2 )	13.4
4	payments and other1	-7.2 ( 7.2 )	-3.1 ( 3.1 )	-5.3 ( 5.3 )	-15.6 ( 15.6 )
5	liability at december 31 2007	$ 11.9	$ 9.0	$ 8.7	$ 29.6
6	net charges and adjustments	4.3	0.8	0.7	5.8
7	payments and other1	-15.0 ( 15.0 )	-4.1 ( 4.1 )	-3.5 ( 3.5 )	-22.6 ( 22.6 )
8	liability at december 31 2008	$ 1.2	$ 5.7	$ 5.9	$ 12.8

1 includes amounts representing adjustments to the liability for changes in foreign currency exchange rates . other reorganization-related charges other reorganization-related charges relate to our realignment of our media businesses into a newly created management entity called mediabrands and the 2006 merger of draft worldwide and foote , cone and belding worldwide to create draftfcb . charges related to severance and terminations costs and lease termination and other exit costs . we expect charges associated with mediabrands to be completed during the first half of 2009 . charges related to the creation of draftfcb in 2006 are complete . the charges were separated from the rest of our operating expenses within the consolidated statements of operations because they did not result from charges that occurred in the normal course of business. .

Previous questions in this conversation: what was the value of liability in 2007? what was it in 2003? what is the sum of those 2 years?
Previous answers: 1.2 5.7 6.9
Question: what is the total sum including the 2001 value?
Answer: 12.8
notes to consolidated financial statements 2014 ( continued ) ( amounts in millions , except per share amounts ) a summary of the remaining liability for the 2007 , 2003 and 2001 restructuring programs is as follows : program program program total .

1	2007 program	2003 program	2001 program	total
2	liability at december 31 2006	$ 2014	$ 12.6	$ 19.2	$ 31.8
3	net charges ( reversals ) and adjustments	19.1	-0.5 ( 0.5 )	-5.2 ( 5.2 )	13.4
4	payments and other1	-7.2 ( 7.2 )	-3.1 ( 3.1 )	-5.3 ( 5.3 )	-15.6 ( 15.6 )
5	liability at december 31 2007	$ 11.9	$ 9.0	$ 8.7	$ 29.6
6	net charges and adjustments	4.3	0.8	0.7	5.8
7	payments and other1	-15.0 ( 15.0 )	-4.1 ( 4.1 )	-3.5 ( 3.5 )	-22.6 ( 22.6 )
8	liability at december 31 2008	$ 1.2	$ 5.7	$ 5.9	$ 12.8

1 includes amounts representing adjustments to the liability for changes in foreign currency exchange rates . other reorganization-related charges other reorganization-related charges relate to our realignment of our media businesses into a newly created management entity called mediabrands and the 2006 merger of draft worldwide and foote , cone and belding worldwide to create draftfcb . charges related to severance and terminations costs and lease termination and other exit costs . we expect charges associated with mediabrands to be completed during the first half of 2009 . charges related to the creation of draftfcb in 2006 are complete . the charges were separated from the rest of our operating expenses within the consolidated statements of operations because they did not result from charges that occurred in the normal course of business. .

Previous questions in this conversation: what was the value of liability in 2007? what was it in 2003? what is the sum of those 2 years? what is the total sum including the 2001 value?
Previous answers: 1.2 5.7 6.9 12.8
Question: what is the average per year?
Answer: 4.26667
performance graph comparison of five-year cumulative total return the following graph and table compare the cumulative total return on citi 2019s common stock , which is listed on the nyse under the ticker symbol 201cc 201d and held by 65691 common stockholders of record as of january 31 , 2018 , with the cumulative total return of the s&p 500 index and the s&p financial index over the five-year period through december 31 , 2017 . the graph and table assume that $ 100 was invested on december 31 , 2012 in citi 2019s common stock , the s&p 500 index and the s&p financial index , and that all dividends were reinvested . comparison of five-year cumulative total return for the years ended date citi s&p 500 financials .

1	date	citi	s&p 500	s&p financials
2	31-dec-2012	100.0	100.0	100.0
3	31-dec-2013	131.8	132.4	135.6
4	31-dec-2014	137.0	150.5	156.2
5	31-dec-2015	131.4	152.6	153.9
6	31-dec-2016	152.3	170.8	188.9
7	31-dec-2017	193.5	208.1	230.9

.

Question: what is the value of citi common stock in 2017 less an initial $100 investment?
Answer: 93.5
performance graph comparison of five-year cumulative total return the following graph and table compare the cumulative total return on citi 2019s common stock , which is listed on the nyse under the ticker symbol 201cc 201d and held by 65691 common stockholders of record as of january 31 , 2018 , with the cumulative total return of the s&p 500 index and the s&p financial index over the five-year period through december 31 , 2017 . the graph and table assume that $ 100 was invested on december 31 , 2012 in citi 2019s common stock , the s&p 500 index and the s&p financial index , and that all dividends were reinvested . comparison of five-year cumulative total return for the years ended date citi s&p 500 financials .

1	date	citi	s&p 500	s&p financials
2	31-dec-2012	100.0	100.0	100.0
3	31-dec-2013	131.8	132.4	135.6
4	31-dec-2014	137.0	150.5	156.2
5	31-dec-2015	131.4	152.6	153.9
6	31-dec-2016	152.3	170.8	188.9
7	31-dec-2017	193.5	208.1	230.9

.

Previous questions in this conversation: what is the value of citi common stock in 2017 less an initial $100 investment?
Previous answers: 93.5
Question: what is that divided by 100?
Answer: 0.935
stockholder return performance graphs the following graph compares the cumulative 5-year total stockholder return on our common stock relative to the cumulative total return of the nasdaq composite index and the s&p 400 information technology index . the graph assumes that the value of the investment in our common stock and in each index ( including reinvestment of dividends ) was $ 100 on december 29 , 2007 and tracks it through december 29 , 2012 . comparison of 5 year cumulative total return* among cadence design systems , inc. , the nasdaq composite index , and s&p 400 information technology cadence design systems , inc . nasdaq composite s&p 400 information technology 12/29/1212/31/111/1/111/2/101/3/0912/29/07 *$ 100 invested on 12/29/07 in stock or 12/31/07 in index , including reinvestment of dividends . indexes calculated on month-end basis . copyright a9 2013 s&p , a division of the mcgraw-hill companies inc . all rights reserved. .

1	12/29/2007	1/3/2009	1/2/2010	1/1/2011	12/31/2011	12/29/2012
2	cadence design systems inc .	100.00	22.55	35.17	48.50	61.07	78.92
3	nasdaq composite	100.00	59.03	82.25	97.32	98.63	110.78
4	s&p 400 information technology	100.00	54.60	82.76	108.11	95.48	109.88

the stock price performance included in this graph is not necessarily indicative of future stock price performance .

Question: what is the difference of the price of cadence design from 2007 to 2012?
Answer: -21.08
stockholder return performance graphs the following graph compares the cumulative 5-year total stockholder return on our common stock relative to the cumulative total return of the nasdaq composite index and the s&p 400 information technology index . the graph assumes that the value of the investment in our common stock and in each index ( including reinvestment of dividends ) was $ 100 on december 29 , 2007 and tracks it through december 29 , 2012 . comparison of 5 year cumulative total return* among cadence design systems , inc. , the nasdaq composite index , and s&p 400 information technology cadence design systems , inc . nasdaq composite s&p 400 information technology 12/29/1212/31/111/1/111/2/101/3/0912/29/07 *$ 100 invested on 12/29/07 in stock or 12/31/07 in index , including reinvestment of dividends . indexes calculated on month-end basis . copyright a9 2013 s&p , a division of the mcgraw-hill companies inc . all rights reserved. .

1	12/29/2007	1/3/2009	1/2/2010	1/1/2011	12/31/2011	12/29/2012
2	cadence design systems inc .	100.00	22.55	35.17	48.50	61.07	78.92
3	nasdaq composite	100.00	59.03	82.25	97.32	98.63	110.78
4	s&p 400 information technology	100.00	54.60	82.76	108.11	95.48	109.88

the stock price performance included in this graph is not necessarily indicative of future stock price performance .

Previous questions in this conversation: what is the difference of the price of cadence design from 2007 to 2012?
Previous answers: -21.08
Question: what is that divided by 100?
Answer: -0.2108
alexion pharmaceuticals , inc . notes to consolidated financial statements 2014 ( continued ) for the years ended december 31 , 2007 and 2006 , five month period ended december 31 , 2005 , and year ended july 31 , 2005 ( amounts in thousands , except share and per share amounts ) aggregate future minimum annual rental payments for the next five years and thereafter under non-cancellable operating leases ( including facilities and equipment ) as of december 31 , 2007 are: .

1	2008	$ 4935
2	2009	3144
3	2010	3160
4	2011	3200
5	2012	2768
6	thereafter	9934

9 . commitments and contingencies legal proceedings on march 16 , 2007 , pdl biopharma , inc. , or pdl , filed a civil action against alexion in the u.s . district court for the district of delaware . pdl claims willful infringement by alexion of pdl patents due to sales of soliris . pdl seeks unspecified damages , but no less than a reasonable royalty , plus attorney 2019s fees . alexion has denied pdl's claims . in addition , we filed counterclaims seeking declarations of non-infringement and invalidity of certain u.s . patents held by pdl . alexion believes it has good and valid defenses to pdl's claims and intends to vigorously defend the case and pursue its counterclaims . on february 4 , 2008 , sb2 , inc . filed a civil action against alexion in the united states district court for the northern district of california . sb2 , inc . claims willfull infringement by alexion of sb2 , inc . patents due to sales of soliris . sb2 , inc . seeks unspecified monetary damages , equitable relief and attorneys fees . alexion believes it has good and valid defenses to sb2's claims and intends to vigorously defend the case and pursue its counterclaims . the results of such civil actions cannot be predicted with certainty due to their early stages . however , depending on the outcome of these legal matters , the operating results of the company could be materially impacted through adjustments to cost of sales ( see notes 2 , 6 and 15 for additional information related to royalties ) . product supply the large-scale product supply agreement dated december 18 , 2002 , or the lonza agreement , between lonza sales ag , or lonza , and us , relating to the manufacture of soliris , was amended in june 2007 . we amended our supply agreement to provide for additional purchase commitments of soliris of $ 30000 to $ 35000 through 2013 . such commitments may only be cancelled in limited circumstances. .

Question: what was the minimum annual rental payment in 2011?
Answer: 3200
alexion pharmaceuticals , inc . notes to consolidated financial statements 2014 ( continued ) for the years ended december 31 , 2007 and 2006 , five month period ended december 31 , 2005 , and year ended july 31 , 2005 ( amounts in thousands , except share and per share amounts ) aggregate future minimum annual rental payments for the next five years and thereafter under non-cancellable operating leases ( including facilities and equipment ) as of december 31 , 2007 are: .

1	2008	$ 4935
2	2009	3144
3	2010	3160
4	2011	3200
5	2012	2768
6	thereafter	9934

9 . commitments and contingencies legal proceedings on march 16 , 2007 , pdl biopharma , inc. , or pdl , filed a civil action against alexion in the u.s . district court for the district of delaware . pdl claims willful infringement by alexion of pdl patents due to sales of soliris . pdl seeks unspecified damages , but no less than a reasonable royalty , plus attorney 2019s fees . alexion has denied pdl's claims . in addition , we filed counterclaims seeking declarations of non-infringement and invalidity of certain u.s . patents held by pdl . alexion believes it has good and valid defenses to pdl's claims and intends to vigorously defend the case and pursue its counterclaims . on february 4 , 2008 , sb2 , inc . filed a civil action against alexion in the united states district court for the northern district of california . sb2 , inc . claims willfull infringement by alexion of sb2 , inc . patents due to sales of soliris . sb2 , inc . seeks unspecified monetary damages , equitable relief and attorneys fees . alexion believes it has good and valid defenses to sb2's claims and intends to vigorously defend the case and pursue its counterclaims . the results of such civil actions cannot be predicted with certainty due to their early stages . however , depending on the outcome of these legal matters , the operating results of the company could be materially impacted through adjustments to cost of sales ( see notes 2 , 6 and 15 for additional information related to royalties ) . product supply the large-scale product supply agreement dated december 18 , 2002 , or the lonza agreement , between lonza sales ag , or lonza , and us , relating to the manufacture of soliris , was amended in june 2007 . we amended our supply agreement to provide for additional purchase commitments of soliris of $ 30000 to $ 35000 through 2013 . such commitments may only be cancelled in limited circumstances. .

Previous questions in this conversation: what was the minimum annual rental payment in 2011?
Previous answers: 3200.0
Question: what was it in 2010?
Answer: 3160
alexion pharmaceuticals , inc . notes to consolidated financial statements 2014 ( continued ) for the years ended december 31 , 2007 and 2006 , five month period ended december 31 , 2005 , and year ended july 31 , 2005 ( amounts in thousands , except share and per share amounts ) aggregate future minimum annual rental payments for the next five years and thereafter under non-cancellable operating leases ( including facilities and equipment ) as of december 31 , 2007 are: .

1	2008	$ 4935
2	2009	3144
3	2010	3160
4	2011	3200
5	2012	2768
6	thereafter	9934

9 . commitments and contingencies legal proceedings on march 16 , 2007 , pdl biopharma , inc. , or pdl , filed a civil action against alexion in the u.s . district court for the district of delaware . pdl claims willful infringement by alexion of pdl patents due to sales of soliris . pdl seeks unspecified damages , but no less than a reasonable royalty , plus attorney 2019s fees . alexion has denied pdl's claims . in addition , we filed counterclaims seeking declarations of non-infringement and invalidity of certain u.s . patents held by pdl . alexion believes it has good and valid defenses to pdl's claims and intends to vigorously defend the case and pursue its counterclaims . on february 4 , 2008 , sb2 , inc . filed a civil action against alexion in the united states district court for the northern district of california . sb2 , inc . claims willfull infringement by alexion of sb2 , inc . patents due to sales of soliris . sb2 , inc . seeks unspecified monetary damages , equitable relief and attorneys fees . alexion believes it has good and valid defenses to sb2's claims and intends to vigorously defend the case and pursue its counterclaims . the results of such civil actions cannot be predicted with certainty due to their early stages . however , depending on the outcome of these legal matters , the operating results of the company could be materially impacted through adjustments to cost of sales ( see notes 2 , 6 and 15 for additional information related to royalties ) . product supply the large-scale product supply agreement dated december 18 , 2002 , or the lonza agreement , between lonza sales ag , or lonza , and us , relating to the manufacture of soliris , was amended in june 2007 . we amended our supply agreement to provide for additional purchase commitments of soliris of $ 30000 to $ 35000 through 2013 . such commitments may only be cancelled in limited circumstances. .

Previous questions in this conversation: what was the minimum annual rental payment in 2011? what was it in 2010?
Previous answers: 3200.0 3160.0
Question: what is the difference?
Answer: 40
alexion pharmaceuticals , inc . notes to consolidated financial statements 2014 ( continued ) for the years ended december 31 , 2007 and 2006 , five month period ended december 31 , 2005 , and year ended july 31 , 2005 ( amounts in thousands , except share and per share amounts ) aggregate future minimum annual rental payments for the next five years and thereafter under non-cancellable operating leases ( including facilities and equipment ) as of december 31 , 2007 are: .

1	2008	$ 4935
2	2009	3144
3	2010	3160
4	2011	3200
5	2012	2768
6	thereafter	9934

9 . commitments and contingencies legal proceedings on march 16 , 2007 , pdl biopharma , inc. , or pdl , filed a civil action against alexion in the u.s . district court for the district of delaware . pdl claims willful infringement by alexion of pdl patents due to sales of soliris . pdl seeks unspecified damages , but no less than a reasonable royalty , plus attorney 2019s fees . alexion has denied pdl's claims . in addition , we filed counterclaims seeking declarations of non-infringement and invalidity of certain u.s . patents held by pdl . alexion believes it has good and valid defenses to pdl's claims and intends to vigorously defend the case and pursue its counterclaims . on february 4 , 2008 , sb2 , inc . filed a civil action against alexion in the united states district court for the northern district of california . sb2 , inc . claims willfull infringement by alexion of sb2 , inc . patents due to sales of soliris . sb2 , inc . seeks unspecified monetary damages , equitable relief and attorneys fees . alexion believes it has good and valid defenses to sb2's claims and intends to vigorously defend the case and pursue its counterclaims . the results of such civil actions cannot be predicted with certainty due to their early stages . however , depending on the outcome of these legal matters , the operating results of the company could be materially impacted through adjustments to cost of sales ( see notes 2 , 6 and 15 for additional information related to royalties ) . product supply the large-scale product supply agreement dated december 18 , 2002 , or the lonza agreement , between lonza sales ag , or lonza , and us , relating to the manufacture of soliris , was amended in june 2007 . we amended our supply agreement to provide for additional purchase commitments of soliris of $ 30000 to $ 35000 through 2013 . such commitments may only be cancelled in limited circumstances. .

Previous questions in this conversation: what was the minimum annual rental payment in 2011? what was it in 2010? what is the difference?
Previous answers: 3200.0 3160.0 40.0
Question: what is the percent change?
Answer: 0.01266
devon energy corporation and subsidiaries notes to consolidated financial statements 2013 ( continued ) asset divestitures in conjunction with the asset divestitures in 2013 and 2014 , devon removed $ 26 million and $ 706 million of goodwill , respectively , which were allocated to these assets . impairment devon 2019s canadian goodwill was originally recognized in 2001 as a result of a business combination consisting almost entirely of conventional gas assets that devon no longer owns . as a result of performing the goodwill impairment test described in note 1 , devon concluded the implied fair value of its canadian goodwill was zero as of december 31 , 2014 . this conclusion was largely based on the significant decline in benchmark oil prices , particularly after opec 2019s decision not to reduce its production targets that was announced in late november 2014 . consequently , in the fourth quarter of 2014 , devon wrote off its remaining canadian goodwill and recognized a $ 1.9 billion impairment . other intangible assets as of december 31 , 2014 , intangible assets associated with customer relationships had a gross carrying amount of $ 569 million and $ 36 million of accumulated amortization . the weighted-average amortization period for the customer relationships is 13.7 years . amortization expense for intangibles was approximately $ 36 million for the year ended december 31 , 2014 . other intangible assets are reported in other long-term assets in the accompanying consolidated balance sheets . the following table summarizes the estimated aggregate amortization expense for the next five years . year amortization amount ( in millions ) .

1	year	amortization amount ( in millions )
2	2015	$ 45
3	2016	$ 45
4	2017	$ 45
5	2018	$ 45
6	2019	$ 44

.

Question: what is 45 times 4?
Answer: 180